Curcumin Cuts Growth of Large Colorectal Adenomas in 577-Patient RCT

Colorectal cancer is the third most common cancer worldwide, and the vast majority of cases begin as benign adenomatous polyps that slowly enlarge over years. Because curcumin—the primary polyphenol in turmeric—has shown chemopreventive effects in preclinical models, researchers have long sought proof that it can slow or prevent this adenoma-to-carcinoma sequence in humans. The J-CAP-C study, published in the American Journal of Gastroenterology on August 28, 2026, provides the strongest evidence to date: a multicenter, double-blind, placebo-controlled trial in 577 patients with previously resected colorectal neoplasia.

Importantly, the trial did not find that curcumin prevented recurrence outright; rather, it slowed the growth of the adenomas that did return. In clinical practice, this distinction matters: larger adenomas carry a greater risk of progressing to invasive cancer, and guidelines in Japan (and increasingly elsewhere) recommend endoscopic removal of lesions ≥6 mm. Anyone considering curcumin as part of a broader metabolic or dosing calculator-guided strategy should understand that this is chemoprevention evidence, not treatment data for established malignancy. For a deeper look at curcumin’s broader cancer research landscape, see our long-read on curcumin and human cancer evidence.

Below is a detailed breakdown of the trial design, the primary and secondary outcomes, and what these findings mean for patients who use curcumin as part of a wellness or adjunctive strategy.

Table of Contents

• The Study Design
• The Primary Outcome: A Nuanced Null
• The Secondary Outcomes: Size and Burden
• Clinical Implications and Limitations
• Frequently Asked Questions

The Study Design

The trial was conducted across 22 Japanese centers between April 2016 and March 2020. Eligible participants had undergone endoscopic resection of colorectal adenomas and were randomly assigned 1:1 to receive either oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All patients returned for a 2-year colonoscopy. The analysis followed a modified intention-to-treat principle.

Theracurmin is a submicron-particle formulation of curcumin designed to improve absorption. The 180 mg twice-daily dose is roughly equivalent to a much higher dose of standard curcumin powder, because the particle size increases bioavailability. Investigators chose this formulation because earlier pilot studies with standard curcumin had shown minimal plasma levels, whereas Theracurmin achieves measurable circulating concentrations of curcumin and its metabolites.

The Primary Outcome: A Nuanced Null

The primary endpoint was the detection rate of any recurrent colorectal adenomas at the 2-year colonoscopy. Between the curcumin group (n=287) and the placebo group (n=290), there was no significant difference: the risk ratio was 0.98 (95% CI 0.82–1.16). In plain terms, curcumin did not reduce the chance of developing a new adenoma.

However, the authors emphasize that incidence alone may not capture the full biological impact of a chemopreventive agent. Many adenomas detected at 2 years are small (≤5 mm) and carry very low malignant potential. A drug that prevents progression—rather than preventing initiation—could still provide meaningful clinical benefit by keeping lesions small and manageable.

The Secondary Outcomes: Size and Burden

Here the results were striking. The trial prespecified a secondary endpoint focusing on adenomas ≥6 mm, the size threshold that Japanese guidelines recommend for endoscopic resection. In this category, the curcumin group showed a 44% reduction compared with placebo:

• Adenomas ≥6 mm: risk ratio 0.56 (95% CI 0.33–0.95); P=0.04
• Number of adenomas ≥6 mm per patient: significantly lower (P=0.03)
• Median size of all detected adenomas: significantly smaller in the curcumin group (P=0.003)

In exploratory analyses, the effect was more pronounced in men and in patients with a higher baseline adenoma burden (i.e., those who had multiple or larger adenomas at study entry). This suggests curcumin may be most beneficial in higher-risk individuals.

These secondary endpoints are clinically meaningful because larger adenomas are more likely to harbor advanced histology (villous features, high-grade dysplasia) and are more strongly linked to progression to colorectal cancer. Slowing their growth may translate into fewer invasive procedures and a lower long-term cancer risk.

Clinical Implications and Limitations

The trial was well conducted, with a large sample, multicenter design, and double-blind placebo control. The safety profile was favorable: treatment-related adverse events were infrequent and mild, with no serious adverse events attributed to curcumin. This is consistent with decades of observational data on turmeric and curcumin supplementation.

However, several caveats apply:

• Population: The study was conducted in Japanese patients, who may have different dietary curcumin intake, microbiome profiles, and adenoma biology compared with Western populations. Whether the results generalize to other ethnicities is unknown.
• Formulation: The positive result was achieved with Theracurmin, a proprietary submicron formulation. Standard curcumin powder or turmeric spice has far lower bioavailability and may not produce the same plasma levels.
• Primary endpoint miss: Because the overall recurrence rate was not reduced, regulatory agencies would classify this as a negative trial for the primary endpoint. The secondary findings, while statistically significant, are hypothesis-generating and would ideally require confirmation in a dedicated trial powered for size-based endpoints.
• Not cancer treatment: This is chemoprevention in a post-polypectomy population, not treatment for established colorectal cancer. Patients with active cancer should not extrapolate these findings to their treatment strategy.

Overall, the J-CAP-C trial provides the strongest human evidence to date that curcumin can slow the growth of colorectal adenomas, particularly in higher-risk individuals. It adds a meaningful data point to the broader evidence base for curcumin in cancer-related metabolic and anti-inflammatory pathways.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Takayama T, et al. Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Am J Gastroenterol. 2026 Aug 28. doi:10.14309/ajg.0000000000004193. PMID: 42669465.
2. jRCTs061180079 — Japanese Registry of Clinical Trials. J-CAP-C Study.

Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. The trial described is a chemoprevention study in patients with previously resected adenomas, not a cancer treatment trial. Always consult a licensed healthcare provider before starting any supplement, especially if you have a medical condition or are undergoing treatment. The authors and publishers of this content are not responsible for any adverse effects or consequences resulting from the use of any information presented herein.